HomeBiosense Webster Inc.Biosense Webster Launches UnitedbyVision campaign

Biosense Webster Launches UnitedbyVision campaign

Biosense Webster, Inc., has launched of the #UnitedbyVision campaign. Inspired by the ability of the newly-launched CARTO VIZIGO Sheath which allows electrophysiologists to better “see” during procedures to treat atrial fibrillation, the campaign is designed to bring the power of vision to others.

Biosense Webster will be making a charitable donation to the cureblindness.org-Himalayan Cataract Project to provide up to 4,000 vision correction procedures to underserved populations around the world.

“For more than 20 years, Biosense Webster has provided innovative solutions that allow electrophysiologists (EPs) to quickly discover, accurately interpret, and effectively treat atrial fibrillation (AF),” said Uri Yaron, Worldwide President of Biosense Webster, Inc. “In launching the CARTO VIZIGO sheath and the #UnitedbyVision campaign, we are providing EPs the ability to see their sheath on our CARTO mapping system, while providing the gift of vision to thousands in need in the developing world.”

Globally, 217 million people struggle with low vision and another 36 million people are blind; treatable cataracts are a leading cause.[1] Some 18 million needlessly-blind cataract patients still await care, most of them with no place to turn. The Himalayan Cataract Project works to overcome barriers impeding delivery of cataract care to underserved, needlessly blind people in the developing world. Their doctors have restored vision to hundreds of thousands of people around the world.

The CARTO VIZIGO Launch: The CARTO VIZIGO Bi-directional Guiding Sheath is the first commercially available steerable guiding sheath that can be visualized on the CARTO 3 System during a catheter ablation procedure, reducing the need for EPs to depend solely on fluoroscopy to determine its location.

A sheath is an introducer routinely used by EPs to facilitate catheter access, stability, and tissue contact when targeting ablation sites to treat arrhythmias such as AF. Many EPs use fluoroscopy to identify the location of the sheath, therefore requiring the use of lead to protect themselves from radiation during the procedure. Research shows that up to 62% of medical staff suffer from chronic musculoskeletal pain from wearing these heavy protective garments.[2] Additionally, patients are exposed to a radiation dose equivalent to 830 chest x-rays during a conventional radiofrequency (RF) ablation procedure.[3]

“CARTO VIZIGO is an advancement that elevates the standard of care that EPs in America deliver to patients with atrial fibrillation,” said Daniella Cramp, U.S. President of Biosense Webster, Inc. “Our customers will be delighted to know that we are also supporting care for disadvantaged patients living with cataracts. Together, we are truly changing the course of human health for better.”

About Atrial Fibrillation (AF):  An estimated 33 million people worldwide have been diagnosed with AF and its prevalence is projected to increase significantly as the population ages.[4] Most AF patients who receive catheter ablation treatment experience a long-term reduction in the number of episodes of the arrhythmia and the severity of symptoms. In fact, many achieve a permanent return to normal heart rhythm. As with any medical treatment, individual results may vary. Only a cardiologist or electrophysiologist can determine whether ablation is an appropriate course of treatment. There are potential risks including bleeding, swelling or bruising at the catheter insertion site, and infection. More serious complications are rare, which can include damage to the heart or blood vessels; blood clots (which may lead to stroke); heart attack, or death. These risks need to be discussed with your doctor and recovery takes time.

The Himalayan Cataract Project and its extensive network of partners work across South Asia and Sub-Saharan Africa to bring world-class eye care to the needlessly blind through quality care, clinical training and the establishment of first-rate ophthalmic infrastructures. Co-founder Sanduk Ruit MD, born in Nepal, educated in India, together with American ophthalmologist, Geoff Tabin MD, recognized the unmet eye health need in the Himalayas and made a vow in 1995 to eliminate preventable and treatable blindness. Visit https://www.cureblindness.org/ to learn more.


References

[1] World Health Organization. Blindness and Visual Impairment: Key Facts. http://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment

[2] Ref: Orme JA Occupational Hazards of Interventional Cardiologists: Prevalence of Orthopedic Health Problems in Contemporary Practice Catheterization and Cardiovascular Interventions 63:407–411 (2004)

[3] *Effective dose of 16.6 (6.6-59.2) mSv Ref: Picano et al. Risks Related to Fluoroscopy Radiation Associated with EP Procedures. JAFIB Aug-Sep 2014

[4] European Heart Journal, Volume 37, Issue 38, 7 October 2016, Pages 2893–2962, https://doi.org/10.1093/eurheartj/ehw210

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy